Navigation Links
Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
Date:11/9/2010

KIHEI, Hawaii, Nov. 9, 2010 /PRNewswire/ -- Functional Nutriments, the makers of Apocaps®, the world's first dietary apoptogens for dogs, announced it was awarded a $244,479 federal grant to research the application of its apoptosis-inducing formula for human cancers.

The grant is part of the U.S. government's $1 Billion Qualifying Therapeutic Discovery Project, overseen by the Internal Revenue Service and the U.S. Department of Health and Human Services. The QTDP program offers funding to small companies creating medical therapies with the potential to reduce health care costs, create jobs, improve U.S. competitiveness, or significantly advance the goal of curing cancer within the next 30 years.

It was a competitive awards process with applications being reviewed by the National Institutes of Health. The program was oversubscribed with about $10 Billion in requests. The projects that won the federal grants and tax credits were seen as the most promising by the NIH review committee. The cash grant of $244,479 was the highest amount a single project could receive.

"We are pleased for the recognition and to receive this grant to further our research and development in the use of apoptogens to combat cancer," said James Jacobson, Functional Nutriment's Chief Executive Officer. "We believe that this grant is further validation that our research may one day extend beyond dogs and help people who are fighting cancer."

Chief Medical Officer and company co-founder Dr. Demian Dressler, DVM, said, "Apoptosis is a such a fundamental biological process and the ability to induce it in cancer cells using natural apoptogens suggests enormous potential for human cancer patients."  

About Functional Nutriments

Functional Nutriments is a privately held company based in Maui, Hawaii focused on first-in-class therapeutics for cancer. The core focus of its research is dietary apoptogens which induce the normal biological process of apoptosis. The first application of the company's research is the nutraceutical Apocaps® CX for dogs (http://apocaps.com), which was released in 2010. Through further research and testing, the company's objective is to apply its patent-pending formulations to drugs for human cancer patients.

Safe Harbor Statement

This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding Functional Nutriments' use of dietary apoptogens for treating cancer. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; the protection and market exclusivity provided by Company's intellectual property; risks related to drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.

Contact:

James Jacobson
CEO
Functional Nutriments, LLC
Tel: (808) 660-4230 ext. 88
Email: jj(at)FunctionalNutriments.com
http://FunctionalNutriments.com



This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Functional Nutriments, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Creating Functional Hepatic Tissue in a Bioengineered Human Liver
2. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
3. Prostate cancer risk variant found to be in a functional DNA sequence linked with disease
4. Scientists demonstrate multibeam, multi-functional lasers
5. Scientists develop novel method to generate functional hepatocytes for drug testing
6. A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders
7. MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC/eClinical Offering
8. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
9. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
10. GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
11. RVX-208 Data Demonstrates Increase in Functional HDL Particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):